NO20026286D0 - Nye peptider - Google Patents
Nye peptiderInfo
- Publication number
- NO20026286D0 NO20026286D0 NO20026286A NO20026286A NO20026286D0 NO 20026286 D0 NO20026286 D0 NO 20026286D0 NO 20026286 A NO20026286 A NO 20026286A NO 20026286 A NO20026286 A NO 20026286A NO 20026286 D0 NO20026286 D0 NO 20026286D0
- Authority
- NO
- Norway
- Prior art keywords
- new peptides
- growth factor
- vascular endothelial
- endothelial growth
- receptor
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 abstract 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 abstract 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 238000002059 diagnostic imaging Methods 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20026286A NO20026286D0 (no) | 2002-12-30 | 2002-12-30 | Nye peptider |
| AT03781116T ATE386050T1 (de) | 2002-12-30 | 2003-12-29 | Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden |
| PCT/NO2003/000444 WO2004058802A1 (en) | 2002-12-30 | 2003-12-29 | Peptides that bind to the heparin binding domian of vegf and vegfr-2 |
| DE60319135T DE60319135D1 (de) | 2002-12-30 | 2003-12-29 | Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden |
| EP03781116A EP1578785B1 (en) | 2002-12-30 | 2003-12-29 | Peptides that bind to the heparin binding domain of vegf and vegfr-2 |
| US10/540,431 US20060089307A1 (en) | 2002-12-30 | 2003-12-29 | Peptides that bind to the heparin binding domian of vegf and vegfr-2 |
| AU2003288810A AU2003288810A1 (en) | 2002-12-30 | 2003-12-29 | Peptides that bind to the heparin binding domian of vegf and vegfr-2 |
| JP2004563063A JP2006523608A (ja) | 2002-12-30 | 2003-12-29 | Ｖｅｇｆ及びｖｅｇｆｒ−２のヘパリン結合ドメインに結合するペプチド |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20026286A NO20026286D0 (no) | 2002-12-30 | 2002-12-30 | Nye peptider |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20026286D0 true NO20026286D0 (no) | 2002-12-30 |
Family
ID=19914347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20026286A NO20026286D0 (no) | 2002-12-30 | 2002-12-30 | Nye peptider |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060089307A1 (https=) |
| EP (1) | EP1578785B1 (https=) |
| JP (1) | JP2006523608A (https=) |
| AT (1) | ATE386050T1 (https=) |
| AU (1) | AU2003288810A1 (https=) |
| DE (1) | DE60319135D1 (https=) |
| NO (1) | NO20026286D0 (https=) |
| WO (1) | WO2004058802A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
| US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
| US20050100963A1 (en) | 2002-03-01 | 2005-05-12 | Dyax Corporation | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| US7985402B2 (en) | 2002-03-01 | 2011-07-26 | Bracco Suisse Sa | Targeting vector-phospholipid conjugates |
| US7666979B2 (en) | 2002-03-01 | 2010-02-23 | Bracco International B.V. | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same |
| US7794693B2 (en) * | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
| CA2583399A1 (en) * | 2004-10-14 | 2006-04-27 | Sopherion Therapeutics, Inc. | Anti-angiogenic peptides and methods of use thereof |
| CN101272808B (zh) | 2005-01-06 | 2012-03-21 | 通用电气医疗集团股份有限公司 | 光学成像 |
| JP6758022B2 (ja) * | 2012-09-03 | 2020-09-23 | 国立大学法人 東京大学 | 血管内皮細胞増殖因子受容体阻害ペプチド |
| KR101531944B1 (ko) * | 2013-12-24 | 2015-06-29 | 광주과학기술원 | Ｖｅｇｆ에 특이적으로 결합하는 ｖｅｇｆ－ｂｐｂ |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5928900A (en) * | 1993-09-01 | 1999-07-27 | The Rockefeller University | Bacterial exported proteins and acellular vaccines based thereon |
| WO1997002479A2 (en) * | 1995-06-30 | 1997-01-23 | Yale University | Human monoclonal anti-tumor antibodies |
| US5948667A (en) * | 1996-11-13 | 1999-09-07 | Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food | Xylanase obtained from an anaerobic fungus |
| WO1999010498A2 (en) * | 1997-08-27 | 1999-03-04 | Pioneer Hi-Bred International, Inc. | Genes encoding enzymes for lignin biosynthesis and uses thereof |
| WO1999014321A1 (en) * | 1997-09-17 | 1999-03-25 | The Walter And Eliza Hall Institute Of Medical Research | Novel therapeutic molecules |
| AU757554B2 (en) * | 1998-02-11 | 2003-02-27 | Bracco International B.V. | Angiogenesis targeting molecules |
| EP1248642A4 (en) * | 2000-01-18 | 2005-05-18 | Ludwig Inst Cancer Res | PEPTIDOMIMETIC INHIBITOR OF VEGF-D / VEGF-C / VEGF |
| CA2399080C (en) * | 2000-02-03 | 2013-05-21 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
| CA2327208A1 (en) * | 2000-11-30 | 2002-05-30 | The Government Of The United States Of America | Methods of increasing distribution of therapeutic agents |
| MXPA04000564A (es) * | 2001-07-20 | 2005-02-17 | Univ Zuerich | Composiciones y metodos para uso de agentes bioactivos derivados de aminoacidos sulfatados y sulfonados. |
| CA2666005C (en) * | 2002-03-01 | 2016-01-19 | Dyax Corp. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
-
2002
- 2002-12-30 NO NO20026286A patent/NO20026286D0/no unknown
-
2003
- 2003-12-29 US US10/540,431 patent/US20060089307A1/en not_active Abandoned
- 2003-12-29 AU AU2003288810A patent/AU2003288810A1/en not_active Abandoned
- 2003-12-29 AT AT03781116T patent/ATE386050T1/de not_active IP Right Cessation
- 2003-12-29 WO PCT/NO2003/000444 patent/WO2004058802A1/en not_active Ceased
- 2003-12-29 EP EP03781116A patent/EP1578785B1/en not_active Expired - Lifetime
- 2003-12-29 JP JP2004563063A patent/JP2006523608A/ja active Pending
- 2003-12-29 DE DE60319135T patent/DE60319135D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE60319135D1 (de) | 2008-03-27 |
| AU2003288810A1 (en) | 2004-07-22 |
| US20060089307A1 (en) | 2006-04-27 |
| ATE386050T1 (de) | 2008-03-15 |
| EP1578785B1 (en) | 2008-02-13 |
| EP1578785A1 (en) | 2005-09-28 |
| WO2004058802A1 (en) | 2004-07-15 |
| JP2006523608A (ja) | 2006-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| DE60028970D1 (de) | An her2 bindende peptidverbindungen | |
| DE60220719D1 (de) | Antikörper gegen das muc18-antigen | |
| PT1187918E (pt) | Antagonistas de tek | |
| EP1767544A3 (en) | Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2 | |
| DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| EP2447280A3 (en) | VEGF analogs and methods of use | |
| EA201100694A1 (ru) | Антитело к cd38 человека и его применение | |
| EA201070636A1 (ru) | Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения | |
| EA201070730A1 (ru) | Гуманизированные антитела, специфичные к фактору фон виллебранда | |
| NO20026286D0 (no) | Nye peptider | |
| EA200601217A1 (ru) | Новые конденсированные пирролокарбазолы | |
| MA27880A1 (fr) | Derives de tetrahydrocarbazole et leur utilisation pharmaceutique | |
| WO2004058803A3 (en) | Peptides that bind of the vegfr-2 | |
| DE60027905D1 (de) | Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung | |
| EA200601288A1 (ru) | Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение | |
| DE60135158D1 (de) | Antagonisten des ige-rezeptors | |
| DE602004019541D1 (de) | Cycloalkyläbü kondensierte indole | |
| ATE480552T1 (de) | Stq-peptide | |
| DE60312684D1 (de) | Plazenta-wachstumsfaktor als target für die behandlung von osteoporose | |
| ATE546154T1 (de) | Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung | |
| ATE509957T1 (de) | An die a2-domäne bindende, humane inhibitorische anti-faktor-viii-antikörper | |
| WO2023166318A3 (en) | Therapeutic antibodies | |
| EA200600314A1 (ru) | Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях | |
| ATE324905T1 (de) | Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall |